Program
vilzemetkib
Also written as “AL2846 capsule”, “AL2846 capsules” and “AL2846”.
In Sino Biopharmaceutical's pipeline, AXL/MET酪氨酸激酶抑制剂
. Its studies are mostly in Thyroid Neoplasms · Ovarian Neoplasms · Neurofibromatoses · Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 82 open or running | phase 3since Feb 24, 2025 | May 16, 2016 | Jan 2027phase 3 · NCT06860971 |
- Named in Sino Biopharmaceutical’s own pipeline as
AL2846
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 16, 2016First study: phase 1 study in Advanced CancerFirst studyNCT02779699 · 20 enrolled · China
- Mar 25, 2020Phase 2 study in Bone Metastatic Non-small Cell Lung CancerNCT04325776 · 60 enrolled · China
- Aug 10, 2021Phase 2 study in NeurofibromatosesNCT05011019 · 22 enrolled · China
- Feb 16, 2023Phase 2 study in Differentiated Thyroid CancerNCT05745363 · 33 enrolled · China
- Apr 4, 2023Phase 2 study in Ovarian NeoplasmsNCT05815862 · 29 enrolled · China
- Oct 31, 2023Phase 1 study in Solid TumorNCT06116240 · 135 enrolled · China
- Feb 19, 2024Phase 2 study in Pancreatic NeoplasmsNCT06278493 · 34 enrolled · China
- Feb 24, 2025Phase 3 study in Thyroid NeoplasmsNCT06860971 · 144 planned · China
Ahead
- Jan 2027Primary completion: phase 3 study in Thyroid NeoplasmsNCT06860971
TargetBeta
“AXL/MET酪氨酸激酶抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zanzalintinibrule | Exelixis | phase 3 | 17 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06860971Thyroid Neoplasms · China | 3 | Recruiting | Jan 2027 | 144 |
| NCT06278493Pancreatic Neoplasms · China | 2 | Completed | Oct 25, 2021 | 34 |
| NCT06116240Solid Tumor · China | 1 | Active, not recruiting | Dec 2023 | 135 |
| NCT05815862Ovarian Neoplasms · China | 2 | Completed | Aug 20, 2025 | 29 |
| NCT05745363Differentiated Thyroid Cancer · China | 2 | Completed | Nov 13, 2025 | 33 |
| NCT05011019Neurofibromatoses · China | 2 | Terminated | Feb 2, 2024 | 22 |
| NCT04325776Bone Metastatic Non-small Cell Lung Cancer · China | 2 | UNKNOWN | May 2021 | 60 |
| NCT02779699Advanced Cancer · China | 1 | UNKNOWN | Oct 2020 | 20 |
How it is read
Names in the registry
- “AL2846 capsule”, 3 entries
- “AL2846 capsules”, 2 entries
- “AL2846”, 2 entries
- “AL2846 Capsules”, 1 entry
Conditions, from the studies’ own filings
- Thyroid Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
- Neurofibromatoses, 1 study
- Pancreatic Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.